It is important that nurses talk with their patients about what kind of adverse events to expect while being treated for HER2-positive breast cancer.
When patients with HER2-positive breast cancer know what kind of adverse events to look out for, they tend to have better communication with their healthcare team and, as a result, better compliance and outcomes, according to Madeline Kuiper, MSN, RN, OCN, an oncology nurse practitioner at UCLA.
Transcription
Unfortunately, there are side effects associated with HER2 therapies, as there are with multiple other types of treatments. But if you can explain that to a patient and help them look for and and understand potential side effects, and actually try to institute practices to mitigate those, patients tend to do much better on therapy, and tend to then commit to their therapy and stay on their therapy consistently. Then we can tend to get long-term therapy in compliance with that. Particularly, my setting is more of a metastatic setting. So I have patients who have been on HER2 therapies for 20 years. And they've done very well because [they're] great drugs, but also because we spend a lot of time going over potential side effects and how to manage them.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
ESR1 Testing Is Crucial in Second-line HR+, HER2- Metastatic Breast Cancer
September 20th 2024During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in particular with the use of elacestrant, in HR-positive, HER2-negative metastatic breast cancer.